Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals develops oral antiviral therapeutics for serious viral diseases. The company uses a proprietary nucleos(t)ide prodrug platform focused on single-stranded RNA viruses and is building a pipeline that includes bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, for hepatitis C virus treatment.
Recurring Atea news covers clinical and preclinical antiviral development, including HCV Phase 3 studies such as C-BEYOND and C-FORWARD, hepatitis E virus candidates including AT-587 and AT-2490, scientific conference presentations, financial results, and business updates tied to pipeline execution.
Atea Pharmaceuticals (Nasdaq: AVIR) reported second quarter 2026 results and key viral hepatitis pipeline progress. The Phase 3 C-BEYOND trial of bemnifosbuvir/ruzasvir (BEM/RZR) for HCV met its primary and secondary non-inferiority endpoints versus sofosbuvir/velpatasvir, with sustained virologic response (SVR) of 93.9% vs. 94.8% in the mITT population (n=905). Non‑cirrhotic patients achieved a 93.5% SVR with 8 weeks of BEM/RZR vs. 94.6% with 12 weeks of SOF/VEL; cirrhotic patients had 95.4% SVR in both arms. BEM/RZR was generally safe and well tolerated with no drug‑related serious adverse events.
Atea completed enrollment of its second Phase 3 trial, C-FORWARD, with over 880 patients across 17 countries and expects topline data in early Q1 2027, targeting an NDA submission in Q2 2027. A first‑in‑human Phase 1 trial of AT‑587 for chronic HEV started in July. At June 30, 2026, cash, cash equivalents and marketable securities were $219.5 million (vs. $301.8 million at December 31, 2025). Q2 2026 research and development expense was $28.2 million (down from $32.3 million), general and administrative expense was $6.9 million (down from $9.1 million), and net loss was $32.9 million, or $0.41 per share, compared to $37.2 million, or $0.44 per share, a year earlier.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on Wednesday, August 12, 2026, at 4:30 p.m. ET to discuss its second quarter 2026 financial results and provide a business update. Investors can access the webcast via the Investor Relations section of Atea’s website under “Events and Presentations,” or join by telephone using the U.S. number 1-877-407-0779, international number 1-201-389-0914, and conference ID 13761501. An archived webcast will be available on the company’s website approximately two hours after the call and will remain accessible for at least 90 days.
Atea Pharmaceuticals (Nasdaq: AVIR) reported positive topline Phase 3 C-BEYOND results in North America for its once-daily fixed-dose combination bemnifosbuvir/ruzasvir (BEM/RZR) in chronic hepatitis C virus (HCV). In the modified intent-to-treat population (n=905), BEM/RZR achieved a 93.9% sustained virologic response (SVR) at Week 24 versus 94.8% for standard-of-care sofosbuvir/velpatasvir (SOF/VEL; Epclusa), meeting the primary endpoint of statistical non-inferiority within a prespecified 5% margin.
In patients without cirrhosis (n=721), 8 weeks of BEM/RZR achieved a 93.5% SVR versus 12 weeks of SOF/VEL with 94.6% SVR. In patients with cirrhosis (n=184), 12 weeks of each regimen yielded 95.4% SVR in both arms. Secondary endpoints, including per-protocol analysis, also met statistical non-inferiority. BEM/RZR was generally safe and well tolerated, with no drug-related serious adverse events or drug-related early discontinuations and safety comparable between arms. C-FORWARD, the companion Phase 3 trial outside North America with more than 880 patients enrolled, remains on track to report topline results in early 2027.
Atea Pharmaceuticals (Nasdaq: AVIR) has initiated a first-in-human Phase 1 clinical trial of AT-587, an oral nucleotide analog in development for hepatitis E virus (HEV), a serious liver disease with no approved therapies and high risk for immunocompromised patients, including transplant recipients.
The randomized, double-blind, placebo-controlled study in healthy volunteers features single ascending dose, multiple ascending dose, and food-effect components, with dose escalation guided by emerging safety and pharmacokinetic data. Preclinical results presented at EASL 2026 showed AT-587 is 30–150 times more potent in vitro against HEV than sofosbuvir and ribavirin, demonstrated in vivo activity in an HEV genotype 3 gerbil model, showed no in vitro toxicity, exhibited activity against several other viruses, and retained potency against ribavirin and sofosbuvir resistance strains.
Atea Pharmaceuticals (Nasdaq: AVIR) completed patient enrollment in C-FORWARD, its Phase 3 trial outside North America evaluating the oral combination of bemnifosbuvir and ruzasvir (BEM/RZR) for chronic hepatitis C virus (HCV).
C-FORWARD enrolled over 880 treatment‑naïve patients at ~120 sites in 17 countries, comparing BEM/RZR with sofosbuvir/velpatasvir. Topline results are expected around year-end 2026, with C-BEYOND topline data on track for mid‑2026. The program is described by Atea as the first global Phase 3 head‑to‑head DAA regimen comparison for HCV.
Atea Pharmaceuticals (Nasdaq: AVIR) reported Phase 1 data showing its fixed-dose hepatitis C regimen bemnifosbuvir/ruzasvir (BEM/RZR) has a low risk of drug-drug interactions with common medicines including omeprazole, digoxin and rosuvastatin.
Atea also presented preclinical data for AT-587, a potential first-in-class hepatitis E antiviral with high in vitro potency and in vivo efficacy.
Atea Pharmaceuticals (Nasdaq: AVIR) will present three abstracts at the EASL 2026 Congress in Barcelona from May 27–30. Two posters cover clinical data on its fixed-dose combination of bemnifosbuvir and ruzasvir for hepatitis C, while a top poster highlights preclinical data for AT-587, Atea’s lead hepatitis E candidate.
Atea Pharmaceuticals (Nasdaq: AVIR) reported first quarter 2026 results and clinical progress. Cash, cash equivalents and marketable securities were $256.0 million at March 31, 2026, down from $301.8 million. Net loss was $45.4 million (basic and diluted loss per share $0.57).
Phase 3 HCV trials remain on track, with C-BEYOND topline data expected mid-2026 and C-FORWARD around year-end 2026. Preclinical data support AT-587 as lead HEV candidate, with Phase 1 initiation targeted for mid-2026.
Atea Pharmaceuticals (Nasdaq: AVIR) will host a live conference call and audio webcast on May 12, 2026 at 4:30 p.m. ET to report first quarter results for the period ended March 31, 2026 and provide a business update. The webcast will be archived on the company's investor site approximately two hours after the call and remain available for at least 90 days.
ReAlta Life Sciences (NASDAQ:AVIR) appointed Howard Berman, Ph.D. as Chairman and CEO and Kia Motesharei, Ph.D. as President and COO on March 24, 2026.
The hires add capital markets, deal-making, and late-stage clinical development experience as ReAlta advances pegtarazimod into late-stage trials for HIE and other indications.